US Senator
John Hickenlooper Authored & Sponsored Legislation
Co-Sponsor of Legislation
US
Us Congress 2025-2026 Regular Session
Us Congress Senate Bill SB383
Introduced
2/4/25
Refer
2/4/25
JOBS Act of 2025 Jumpstart Our Businesses by Supporting Students Act of 2025
US
Us Congress 2025-2026 Regular Session
Us Congress Senate Bill SB391
Introduced
2/4/25
Refer
2/4/25
Access to Counsel Act of 2025
US
Us Congress 2025-2026 Regular Session
Us Congress Senate Bill SB398
Introduced
2/4/25
Refer
2/4/25
NO BAN Act National Origin-Based Antidiscrimination for Nonimmigrants Act
US
Us Congress 2025-2026 Regular Session
Us Congress Senate Bill SB410
Introduced
2/5/25
Refer
2/5/25
Love Lives On Act of 2025
US
Us Congress 2025-2026 Regular Session
Us Congress Senate Bill SB422
Introduced
2/5/25
Refer
2/5/25
Right to Contraception Act
US
Us Congress 2025-2026 Regular Session
Us Congress Senate Bill SB428
Introduced
2/5/25
Refer
2/5/25
Report Pass
3/12/25
SAFE Orbit Act Situational Awareness of Flying Elements in Orbit Act
US
Us Congress 2025-2026 Regular Session
Us Congress Senate Bill SB429
Introduced
2/5/25
Refer
2/5/25
STRATEGIC Minerals Act Securing Trade and Resources for Advanced Technology, Economic Growth, and International Commerce in Minerals Act
US
Us Congress 2025-2026 Regular Session
Us Congress Senate Bill SB437
Introduced
2/5/25
Refer
2/5/25
Caring for All Families Act
US
Us Congress 2025-2026 Regular Session
Us Congress Senate Bill SB453
Introduced
2/6/25
Refer
2/6/25
Wildfire Intelligence Collaboration and Coordination Act of 2025
Primary Sponsor of Legislation
US
Us Congress 2025-2026 Regular Session
Us Congress Senate Bill SB43
Introduced
1/9/25
Refer
1/9/25
Skinny Labels, Big Savings ActThis bill provides a statutory safe harbor from patent infringement claims for generic or biosimilar manufacturers that seek or obtain approval for skinny labels of their drugs.Under current law, the Food and Drug Administration (FDA) may approve generic and biosimilar drugs through a process known as skinny labeling, which allows a generic manufacturer to seek approval only for approved uses of the drug that are no longer protected by patents. However, in GlaxoSmithKline LLC v. Teva Pharmaceuticals USA, Inc., a court held that a generic manufacturer may sometimes be liable for patent infringement when it markets skinny label generics.The bill specifically lists the following as actions that are not considered infringement of a method of use claim in a patent under the Federal Food, Drug, and Cosmetic Act:submitting or seeking approval of a skinny label for a generic or biosimilar drug;promoting or commercially marketing a drug with skinny labeling approved by the FDA; ordescribing a drug product approved by the FDA as a generic of, or therapeutically equivalent to, the branded drug.The bill also applies the safe harbor to similar actions under the Public Health Service Act.